By Nigam Arora
Editor’s note: This signal was published on May 28, 2026, in ZYX Buy Alert for paid members.
In general, the time to buy a high quality company’s stock is when it is hated.
Boston Scientific Corp (BSX) has become one of the market’s most hated stocks.
The reason is simple: WATCHMAN FLX™ Pro.
The stock has been hit hard after management warned that stand-alone Watchman procedures are slowing and that growth may remain soft over the next several quarters.
The market reaction has been severe.
The question now is simple:
Has the long-term thesis materially changed, or is the market reacting to a temporary disruption in one important product line?
At this stage, selling Boston Scientific into panic appears premature.
Why Boston Scientific Is Falling
Several factors are pressuring the stock.
- Medical device stocks are out of favor
Investors are aggressively moving money into AI, semiconductors, and other mania trades.
Steady healthcare and medical device companies are increasingly being used as funding sources for hotter sectors.
This pressure is not unique to Boston Scientific.
Ironically, medical device companies may ultimately benefit from AI advances, but for now, the market wants immediate excitement.
- The Watchman problem
Watchman has been one of Boston Scientific’s biggest growth drivers.
The device helps reduce stroke risk in atrial fibrillation patients by closing the left atrial appendage and reducing reliance on blood thinners.
The issue is not that Watchman has stopped growing.
The issue is that stand-alone Watchman procedures have slowed, and management now expects soft near-term growth.
Doctors are increasingly combining Watchman with other procedures, especially ablation treatments.
That may be beneficial over time, but near term it creates disruption.
- Competition is increasing
Boston Scientific still dominates left atrial appendage closure.
However, competitors such as ABT continue pushing alternatives, including Amulet.
Even modest competition can matter when expectations were very high.
- Guidance credibility has taken a hit
Boston Scientific earlier lowered growth expectations for the year.
Even though growth remains respectable by medical device standards, the market rarely reacts kindly when expectations move lower.
How Big Is The Watchman Problem?
This is where investors may be overreacting.
Boston Scientific generated about $5.2 billion in Q1 revenue.
Watchman generated about $506 million.
That means Watchman represents roughly 10% of companywide sales.
In other words, about 90% of Boston Scientific’s revenue comes from somewhere else.
Here is where the rest of the business comes from:
- Electrophysiology (including Farapulse): ~$905M quarterly sales
This includes Boston Scientific’s pulsed field ablation business, one of the strongest growth areas in cardiology.
Atrial fibrillation is increasing, especially among older populations.
The same demographic trend helping Watchman also helps ablation.
- Pacemakers and defibrillators (Cardiac Rhythm Management): ~$578M quarterly sales
An aging population means more rhythm disorders, more pacing needs, and more heart failure management.
- Coronary and vascular therapies: ~$1.2B quarterly sales
Heart disease and vascular disease are not disappearing.
This remains one of Boston Scientific’s largest businesses.
- Endoscopy, Urology, Neuromodulation, and Oncology tools: billions more in recurring procedure demand
These businesses provide diversification beyond cardiovascular care.
No single product drives the entire company.
That matters.
What About Profits?
Boston Scientific does not break out Watchman profits separately.
However, Watchman is likely more important to profits than sales, because implantable medical devices tend to carry attractive margins.
A reasonable estimate is that Watchman may represent low-to-mid teens of operating profits, even though it represents only about 10% of revenue.
Enough to justify treating Boston Scientific as if the entire growth story is broken?
Probably not.
The market appears to be reacting as if Watchman is the entire company.
It is not.
Why The Long-Term Story May Still Be Intact
One of the best times to take a closer look at a quality company is when investors suddenly hate the stock.
That does not mean blindly buying weakness.
It means determining whether the problem is temporary or whether the long-term thesis has truly broken.
There are several reasons the long-term story may still be intact.
1. Aging demographics still matter
This is the part the market may be forgetting.
An aging population means:
- More atrial fibrillation
- More pacemakers
- More defibrillators
- More vascular disease
- More procedures
Boston Scientific sits directly in the middle of these trends.
A temporary slowdown in Watchman does not stop demographic demand.
This is not a one-quarter theme.
It is a multi-decade trend.
2. Watchman may be a pause, not a collapse
The market is acting like Watchman suddenly broke.
That is not what management said.
Management said growth slowed.
Big difference.
Doctors are increasingly combining Watchman with ablation procedures instead of performing Watchman as a stand-alone treatment.
Near-term disruption does not necessarily mean long-term impairment.
3. Boston Scientific remains diversified
Boston Scientific is not a one-product company.
The business spans:
- Electrophysiology
- Defibrillators and pacemakers
- Coronary and vascular therapies
- Endoscopy
- Urology
- Neuromodulation
- Oncology-related procedures
Even if Watchman takes time to recover, the broader business remains substantial.
4. The Penumbra acquisition adds another growth driver
The pending Penumbra acquisition expands Boston Scientific into thrombectomy and neurovascular procedures.
The deal may create near-term earnings dilution.
The market dislikes that.
But strategically, it strengthens Boston Scientific’s cardiovascular ecosystem and expands long-term growth opportunities.
Analogs: Hated Stocks Can Turn Into Big Winners
There is no certainty that Boston Scientific will follow the same path, but history shows that deeply hated stocks can eventually surprise investors.
Consider:
- MU — heavily disliked at one point when memory prices collapsed, and investors questioned the business model.
- AMAT — repeatedly written off during semiconductor downturns.
- INTC — after prolonged disappointment, sentiment became deeply negative.
At different points, these stocks became deeply hated.
Signals were given to buy at depressed prices when sentiment had turned overwhelmingly negative.
Now look at the enormous gains Arora Members have on these stocks.
The expectation is not that Boston Scientific will suddenly behave like Micron.
The point is different.
When sentiment becomes overwhelmingly negative toward both a stock and an entire sector, opportunity sometimes emerges.
Boston Scientific increasingly appears to be entering that zone.
The Antidote To AI Concentration
Arora portfolios are heavily concentrated in AI and semiconductors
That has worked very well.
But concentration risk quietly builds when too much of a portfolio depends on the same theme continuing indefinitely.
Boston Scientific offers a very different exposure.
Instead of depending on GPU demand, hyperscaler capex, or AI spending cycles, Boston Scientific depends on healthcare procedures and aging demographics.
In many ways, Boston Scientific can serve as an antidote to AI concentration.
- Diversification by strategy matters
Most portfolios today are heavily driven by AI-related momentum.
Boston Scientific is driven by an entirely different force: long-term medical demand.
Diversification by strategy is often overlooked, but can be just as important as diversification by sector.
- Growth and value balance
Much of the market leadership has been growth-at-any-price.
Boston Scientific increasingly looks more like a value opportunity after the sharp selloff.
The stock is no longer priced for perfection.
- Money flows can change
Markets move in cycles.
At some point, leadership changes.
If enthusiasm for AI stocks cools, capital can rotate into overlooked sectors, including medical device companies.
No one knows when that shift will happen.
But eventually, something changes.
Time Frame
Patience may be required.
Boston Scientific’s fundamentals are unlikely to improve dramatically over the next two or three quarters.
Watchman challenges may persist.
Management will likely need time to stabilize growth and rebuild confidence.
However, sentiment often changes before fundamentals improve.
If enthusiasm around AI and semiconductor stocks cools, investor interest in steadier medical device businesses could return sooner than expected.
There is another factor to watch.
Tax-loss selling
Tax-loss selling often intensifies between October and December.
If sentiment toward medical device stocks remains weak, Boston Scientific could face additional selling pressure as investors lock in losses.
Ironically, periods of forced selling sometimes create opportunity by pushing prices to artificially depressed levels.
If sentiment does not improve before then, that period may offer a more attractive opportunity to add exposure.
What To Do Now
To learn what to do now, click here to take a 30 day free trial.
Note: Signal(s) to enter, add, reduce, exit, hold or change.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on May 28, 2026, in ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 1% of the content from our paid services. …TO RECEIVE REMAINING 99%, INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES AND SIGNALS IN REAL TIME, TAKE A FREE
TRIAL TO PAID SERVICES.
The Arora Report is one of the only major global investment newsletters that does not employ a single salesperson—because it does not need to. While competitors rely on high-pressure sales tactics, The Arora Report grows purely through results, with satisfied members recommending it to their family and friends.
Join the service that investors trust the most and recommend to family and friends.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
